Puresyn

Executive Summary

Puresyn is a US-based contract development and manufacturing organization (CDMO) founded in 2003, specializing in high-quality plasmid DNA production for the cell and gene therapy industry. The company offers tailored services from early-stage research through commercial cGMP manufacturing, leveraging proprietary purification technology. Its mission is to supply critical starting materials ensuring clients are 'Breakthrough Ready'. With over two decades of experience, Puresyn has established itself as a reliable partner in a rapidly growing sector, supported by its location in Malvern, Pennsylvania, a hub for life sciences. The demand for plasmid DNA is surging as cell and gene therapies progress toward commercialization. Puresyn's focus on quality and scalability positions it to capture market share, though competition from larger CDMOs and emerging players remains intense. The company's private status and lack of disclosed funding suggest a steady, bootstrapped growth trajectory. Key drivers include the increasing number of gene therapy approvals and the need for robust supply chains. Puresyn's success hinges on expanding capacity and securing long-term partnerships with high-profile developers.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Manufacturing Capacity Expansion60% success
• H1 2027Strategic Partnership with a Top 10 Gene Therapy Developer40% success
• 2027FDA Approval of a Client's Gene Therapy Using Puresyn's Plasmid30% success